Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies.
T cell
Trousseau’s syndrome
immune checkpoint inhibitor (ICI)
immune-related adverse events (irAEs)
macrophage
monocyte
non-small-cell lung cancer (NSCLC)
programmed cell death 1 (PD-1)
programmed cell death ligand 1 (PD-L1)
tissue factor (TF)
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
29 May 2019
29 May 2019
Historique:
received:
03
05
2019
revised:
19
05
2019
accepted:
27
05
2019
entrez:
1
6
2019
pubmed:
31
5
2019
medline:
31
5
2019
Statut:
epublish
Résumé
A disruption of immune checkpoints leads to imbalances in immune homeostasis, resulting in immune-related adverse events. Recent case studies have suggested the association between immune checkpoint inhibitors (ICIs) and the disorders of the coagulation-fibrinolysis system, implying that systemic immune activation may impact a balance between clotting and bleeding. However, little is known about the association of coagulation-fibrinolysis system disorder with the efficacy of ICIs. We retrospectively evaluated 83 lung cancer patients who received ICI at Kumamoto University Hospital. The association between clinical outcome and diseases associated with disorders of the coagulation-fibrinolysis system was assessed along with tumor PD-L1 expression. Among 83 NSCLC patients, total 10 patients (12%) developed diseases associated with the disorder of coagulation-fibrinolysis system. We found that disorders of the coagulation-fibrinolysis system occurred in patients with high PD-L1 expression and in the early period of ICI initiation. In addition, high tumor responses (72%) were observed, including two complete responses among these patients. Furthermore, we demonstrate T-cell activation strongly induces production of a primary initiator of coagulation, tissue factor in peripheral PD-L1
Identifiants
pubmed: 31146442
pii: jcm8060762
doi: 10.3390/jcm8060762
pmc: PMC6617319
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Japan Society for the Promotion of Science
ID : P18K15928
Organisme : Takeda Science Foundation
ID : NA
Références
J Exp Med. 1999 Dec 20;190(12):1909-14
pubmed: 10601366
Arterioscler Thromb Vasc Biol. 2004 Jun;24(6):1015-22
pubmed: 15117736
J Clin Oncol. 2004 May 15;22(10):1944-8
pubmed: 15143088
Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2594-604
pubmed: 16990554
Blood. 2007 Sep 15;110(6):1723-9
pubmed: 17496204
Arterioscler Thromb Vasc Biol. 2008 Mar;28(3):387-91
pubmed: 18296594
JAMA. 2008 Nov 19;300(19):2277-85
pubmed: 19017914
J Exp Med. 2009 Jun 8;206(6):1327-37
pubmed: 19451266
Ann Oncol. 2009 Oct;20(10):1619-30
pubmed: 19561038
J Clin Oncol. 2009 Oct 10;27(29):4834-8
pubmed: 19738116
Science. 2010 May 7;328(5979):697-8
pubmed: 20448171
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Arterioscler Thromb Vasc Biol. 2011 May;31(5):1100-7
pubmed: 21393583
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
J Immunol. 2011 Jul 15;187(2):702-7
pubmed: 21670314
Ann Oncol. 2012 Jul;23(7):1672-9
pubmed: 22241897
Nat Rev Drug Discov. 2012 Feb 03;11(3):215-33
pubmed: 22301798
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Rev Immunol. 2012 Apr 10;12(5):339-51
pubmed: 22487654
Curr Cardiol Rev. 2012 Aug;8(3):168-76
pubmed: 22920487
Clin Cancer Res. 2013 Aug 15;19(16):4508-20
pubmed: 23714729
Clin Cancer Res. 2013 Aug 15;19(16):4295-6
pubmed: 23785048
Oncologist. 2013;18(12):1321-9
pubmed: 24212499
Crit Rev Oncol Hematol. 2014 Nov;92(2):71-82
pubmed: 24878433
Mol Cell Biol. 1989 Jun;9(6):2752-5
pubmed: 2503712
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet. 2016 Apr 9;387(10027):1540-50
pubmed: 26712084
J Immunol Res. 2016;2016:4789279
pubmed: 26885534
Lancet. 2016 Apr 30;387(10030):1837-46
pubmed: 26970723
Int J Cardiol. 2016 Sep 1;218:188-195
pubmed: 27236113
Biochemistry (Mosc). 2016 Feb;81(2):114-21
pubmed: 27260391
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Science. 2017 Mar 31;355(6332):1423-1427
pubmed: 28280249
Eur J Cancer. 2017 May;77:88-89
pubmed: 28365531
Br J Pharmacol. 2017 Nov;174(22):3940-3955
pubmed: 28369782
Nat Rev Immunol. 2017 Jun;17(6):349-362
pubmed: 28436425
Proc Natl Acad Sci U S A. 2017 May 9;114(19):4993-4998
pubmed: 28446615
Nature. 2017 May 25;545(7655):495-499
pubmed: 28514441
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Ann Oncol. 2017 Nov 1;28(11):2893-2895
pubmed: 28651328
Sci Rep. 2017 Jul 11;7(1):5149
pubmed: 28698680
PLoS One. 2017 Aug 23;12(8):e0183594
pubmed: 28832681
Ann N Y Acad Sci. 2017 Sep;1404(1):27-48
pubmed: 28833193
J Thorac Oncol. 2017 Dec;12(12):1798-1805
pubmed: 28939128
JAMA Oncol. 2018 Mar 1;4(3):374-378
pubmed: 28975219
Immunity. 2017 Oct 17;47(4):621-634
pubmed: 29045897
Immunity. 2017 Nov 21;47(5):848-861.e5
pubmed: 29126798
Nat Rev Drug Discov. 2018 Mar;17(3):183-196
pubmed: 29217837
Eur J Cancer. 2018 Mar;91:164-166
pubmed: 29289455
N Engl J Med. 2018 Jan 11;378(2):158-168
pubmed: 29320654
J Clin Oncol. 2018 Jun 10;36(17):1714-1768
pubmed: 29442540
Int J Cancer. 2018 Aug 15;143(4):931-943
pubmed: 29516506
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Nat Med. 2018 May;24(5):541-550
pubmed: 29686425
Medicine (Baltimore). 2018 May;97(20):e10772
pubmed: 29768369
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
Eur J Immunol. 2018 Oct;48(10):1764-1767
pubmed: 29981156
Target Oncol. 2018 Aug;13(4):509-515
pubmed: 30006825
Thorac Cancer. 2018 Nov;9(11):1522-1524
pubmed: 30253076
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Immun Inflamm Dis. 2019 Mar;7(1):3-6
pubmed: 30461210
Lancet Haematol. 2019 Jan;6(1):e48-e57
pubmed: 30528137
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Nat Rev Drug Discov. 2019 Mar;18(3):175-196
pubmed: 30622344
Cancers (Basel). 2019 Jan 24;11(2):null
pubmed: 30682845
Cardiovasc Res. 2019 Apr 15;115(5):869-877
pubmed: 30721928
Sci Transl Med. 2019 Feb 13;11(479):null
pubmed: 30760579
Nat Rev Cardiol. 2019 Jun;16(6):325-343
pubmed: 30770894
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
Blood. 1995 Jul 1;86(1):250-7
pubmed: 7795230